Skip to content
Screener

Janux Therapeutics JANX Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue-
EPS-$0.55Miss by $0.07
EPS estimate-$0.48

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$8.0M
EPS estimate-$0.45

Financials

Q2 2025

Income statement

See full
Revenue--100%
Operating income-$45.1M-226%
Net income-$33.9M-468%
EPS (diluted)-$0.55-400%

Balance sheet

See full
Cash & equivalents$52.4M+258%
Total debt$22.2M-6.8%
Total equity$990.5M+50.6%
Total assets$1.0B+49.3%

Cash flow

See full
Operating cash flow-$23.8M-138%
CapEx$473.0K+398%
Free cash flow-$24.3M-140%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.38B-32.8%
Enterprise value$1.35B-34.5%
P/S3,147.5×+3,012×

Profitability

See full
Operating margin-33,002.1%-33,450pp
Net margin-24,064%-24,362pp
FCF margin-13,827.8%-14,159pp

Returns & leverage

See full
Return on equity-12.8%+8.3pp
Debt / equity0×0.0×
Current ratio47×-10.3×

FAQ

When did Janux Therapeutics report Q2 2025 earnings?
Janux Therapeutics (JANX) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Janux Therapeutics's Q2 2025 revenue and EPS?
Janux Therapeutics reported revenue of - and eps of $-0.55 for Q2 2025.
Did Janux Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.48 by $0.07.
How did Janux Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $8.9M a year earlier and eps declined 400.0% from $-0.11.
Where can I find Janux Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105010) and the 10-Q periodic report (0000950170-25-105069) directly on SEC EDGAR. The filing index links above go to sec.gov.